Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

June Lee

Surgical Oncology Palm Springs, FL Medical Doctor

NPI 1285892406 CMS profile 12671

4685 S Congress Ave Ste 201, Palm Springs, FL 33461

Open in the dashboard

General payments

$1,809

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, June Lee of Palm Springs, FL is reported in the CMS Open Payments database as having received $1,809 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $439 4
2024 General $265 3
2023 General $251 2
2022 General $76 3
2021 General $15 1
2020 General $59 3
2019 General $704 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • June Lee
  • Surgical Oncology median
  • Middle half of Surgical Oncology
  • National median

In program year 2025, general payments to June Lee were reported at $439. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.

Show as a table
Year June Lee Surgical Oncology median Middle half National median
2019 $704 $236 $86–$1,064 $163
2020 $59 $130 $47–$648 $114
2021 $15 $160 $53–$943 $132
2022 $76 $199 $76–$782 $149
2023 $251 $246 $95–$854 $160
2024 $265 $271 $106–$1,123 $164
2025 $439 $288 $118–$1,346 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $700 2 payments
  2. Musculoskeletal Transplant Foundation Inc. $310 2 payments
  3. Endomagnetics Ltd $257 3 payments
  4. Mentor Worldwide LLC $141 2 payments
  5. TEI Biosciences Inc $130 1 payment
  6. AxoGen $125 1 payment
  7. TELA Bio, Inc. $43 2 payments
  8. Tactile Systems Technology Inc $43 2 payments
  9. Acera Surgical, Inc. $28 1 payment
  10. Focal Therapeutics, Inc. $16 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,235 17 payments
  2. Travel and Lodging $574 1 payment
Products named General payments · program years 2019–2025
  1. 1588 HD 3 CHIP CAMERA $574 1 payment
  2. Magseed $257 3 payments
  3. Magtrace $257 3 payments
  4. MENTOR MemoryGel Resterilizable Gel Sizer $141 2 payments
  5. SURGIMEND $130 1 payment
  6. SPY-PHI SYSTEM $126 1 payment
  7. Avance Nerve Graft $125 1 payment
  8. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $43 2 payments
  9. FLEXITOUCH $43 2 payments
  10. ACTITOUCH $43 2 payments
  11. Other $175 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

300

Median for General Surgery: 59

Drug cost

$995

Median for General Surgery: $393

Branded share of claims

63%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 97 $447
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 98 $304
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 61 $139
Acetaminophen-Codeine Acetaminophen With Codeine Brand 30 $80
Tramadol Hcl Generic 14 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$243,192

Medicare's payments for the services billed

Medicare patients

245

Average age 75

Services billed

1,385

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Cancer 62%
Arthritis 56%
Osteoporosis 43%
Depression 26%
Ischemic heart disease 24%
Chronic kidney disease 24%
Diabetes 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record